Efficacy Results of a 52-week Trial of Adalimumab in the Treatment of Refractory Sarcoidosis.

Nadera Sweiss(University of Illinois Chicago), Robert P. Baughman(University of Cincinnati), Wei Zhang(Regenerative Medicine Institute), Aileen L. Pangan(AbbVie (United States)), Joe G. N. Garcia(Scripps Research Institute), Philip Caligiuri, Edward T. Naureckas(University of Chicago), Mary E. Strek(University of Chicago), Timothy B. Niewold(Hospital for Special Surgery), Mehdi Mirsaeidi(Jacksonville University), Imre Noth(University of Virginia), D. Kyle Hogarth(MACOM (United States)), Roberto F. Machado(University of Maryland, Baltimore)
PubMed
April 18, 2014
Cited by 120

Related Papers

Confirmatory interleukin-1 receptor antagonist trial in severe sepsis
|Critical Care Medicine|1997|863
ERS clinical practice guidelines on treatment of sarcoidosis
|European Respiratory Journal|2021|579
Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials
|The Lancet|2021|538
The WASOG Sarcoidosis Organ Assessment Instrument: An update of a previous clinical tool.
|PubMed|2014|505
Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial
|Annals of the Rheumatic Diseases|2010|503